Zoledronic Acid Inhibits Human Osteoblast Activities
نویسندگان
چکیده
منابع مشابه
Zoledronic acid inhibits human osteoblast activities.
BACKGROUND Bisphosphonates are potent inhibitors of bone resorption. These kinds of drugs, which are used for the treatment of osteolytic diseases, have been associated with the occurrence of oral osteonecrosis, especially in patients over 60 years old. Current studies have demonstrated that the cytotoxic effects of bisphosphonates on osteoblasts play an important role in oral osteonecrosis dev...
متن کاملZoledronic acid inhibits macrophage SOCS3 expression and enhances cytokine production.
Suppressor of cytokine signaling-3 (SOCS3) has multiple functions including inhibition of Janus kinase (Jak) activity, regulation of protein degradation, and suppression of cytokine signaling. SOCS3 modulates macrophage response to cytokines such as IL-6 and leptin that are systemically induced in obesity. Obesity is a suspected risk factor for SOCS3-related pathology such as rheumatoid arthrit...
متن کاملZoledronic acid inhibits macrophage/microglia-assisted breast cancer cell invasion
The bisphosphonate zoledronic acid (ZA) significantly reduces complications of bone metastasis by inhibiting resident macrophages, the osteoclasts. Recent clinical trials indicate additional anti-metastatic effects of ZA outside the bone. However, which step of metastasis is influenced and whether thisis due to directtoxicity on cancer cells or inhibition of the tumor promoting microenvironment...
متن کاملZoledronic acid inhibits osteosarcoma growth in an orthotopic model.
Zoledronic acid (ZOL) has been shown to reduce osteolysis in bone metastasis. Its efficacy in osteosarcoma has not been convincingly proved in a clinically relevant model for the disease. In vitro, ZOL decreased osteosarcoma cell proliferation, mainly due to an increase in apoptosis in a dose-dependent fashion. There was a decrease in cell migration at >or=10 micromol/L concentrations, but inva...
متن کاملZoledronic acid and angiogenesis.
To the Editors: In a recent issue of Clinical Cancer Research, Santini and co-workers (1) assert that zoledronic acid (ZA) may inhibit several antiangiogenic-related cascades and its metronomic administration could represent a new potential therapy targeting the endothelial-tumor-stroma behavior. We agree with the authors because better targeting of ZA to cells outside bone could more likely be...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Gerontology
سال: 2013
ISSN: 1423-0003,0304-324X
DOI: 10.1159/000351194